Author: Dorron Blumberg

(NewMediaWire) – July 22, 2019 – Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer, and seller of a variety of Cannabidiol (Hemp)-based products, such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate, announced today that it and its wholly-owned subsidiary, NY Hemp Depot LLC, have officially formed a joint venture with NY – SHI, LLC (“NY – SHI”) and EWSD I LLC dba Shi Farms (“Shi Farms”), a proven existing hemp grow and processing company, to aggregate and purchase fully-grown, harvested industrial hemp from third-party farmers in the State of New York.

July 22, 2019 – The South Florida Science Center and Aquarium, in partnership with the Stiles Nicholson Foundation, is accepting applications for the STEM Innovation Awards recognizing leadership, service and collaboration in the field of Science, Technology, Engineering and Math. The application window is open until August 9, 2019.

July 16, 2019 – PathogenDx, Inc., the Arizona based technology company which provides a DNA-based pathogen testing platform for the cannabis, hemp, agriculture and food safety industries announced today that they have entered into a strategic partnership with Nationwide Laboratory Services/The Hayes Division, a national medical lab testing company based in Florida, to deploy PathogenDx’s proprietary microarray technology for rapid strain identification in the dermatological and podiatric fungal testing industry. As part of the terms of the agreement, Nationwide Laboratory Services will create a Laboratory Developed Test (LDT) based on PathogenDx’s testing technology. PathogenDx will serve as the Research & Development platform and Nationwide Labs will serve as the validator and launchpad for the services.

July, 17, 2019 –  Palmetto General Hospital has received the American Heart Association’s Get With The Guidelines®-Heart Failure Gold Plus Quality Achievement Award. The award recognizes the hospital’s commitment to ensuring heart failure patients receive the most appropriate treatment according to nationally recognized, research-based guidelines founded in the latest scientific evidence. The goal is speeding recovery and reducing hospital readmissions for heart failure patients.